Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–18 of 18 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Experimental II- Stimulation Clear all
Recruiting Phase 2 Interventional

Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma

NCT05241249
View directory record Official record
Conditions
Pancreas Cancer
Interventions
Bethanechol, Gemcitabine, nab-paclitaxel
Drug
Lead sponsor
Susan E. Bates
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Sep 2, 2026, 4:40 PM EDT
Completed Not applicable Interventional Results available

Scrambler Trial for Pain in NMOSD

NCT03452176
View directory record Official record
Conditions
Neuromyelitis Optica
Interventions
Scrambler, Scrambler Sham Control
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 4, 2020 · Synced Sep 2, 2026, 4:40 PM EDT
Terminated Not applicable Interventional

To Evaluate the Efficacy of EEG-guided Magnetic Resonant Therapy in War Veterans With Posttraumatic Stress Disorder

NCT02824445
View directory record Official record
Conditions
Post-Traumatic Stress Disorders
Interventions
individualized Transcranial Magnetic Stimulation
Device
Lead sponsor
72nd Medical Group, Tinker Air Force Base
Federal
Eligibility
18 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jan 1, 2020 · Synced Sep 2, 2026, 4:40 PM EDT
Terminated Phase 2 Interventional Results available

Azacitidine and Erythropoietin Versus Azacitidine Alone for Patients With Low-Risk Myelodysplastic Syndromes

NCT00379912
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Azacitidine, Erythropoietin, Azacitidine (Monotherapy)
Drug
Lead sponsor
Larry Cripe, MD
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
9
States / cities
Galesburg, Illinois • Indianapolis, Indiana • Lafayette, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Sep 2, 2026, 4:40 PM EDT
Recruiting Phase 2 Interventional

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

NCT06859424
View directory record Official record
Conditions
AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome), CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), Prolymphocyctic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasm (MPN), Lymphoma, Myelofibrosis
Interventions
Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E, Hematopoietic Cell Transplantation, PTCy (50 mg/kg D3, D4), PTCy (25 mg/kg D3, D4), Post-transplant Tacrolimus, Post-transplant Mycophenolate mofetil, Post-transplant Abatacept, Post-transplant Ruxolitinib, Supportive Care: Growth Factors, Supportive Care: Blood Products, Supportive Care: Infection Prophylaxis, Supportive Care: Intravenous immune globulin (IVIG), Supportive Care: Seizure prophylaxis, Supportive Care: Monitoring and management of CRS, Supportive Care: Prophylaxis against infections, Supportive Care: Prophylaxis against infections, Supportive Care: Lipid elevations, Study treatment compliance, Prohibited Concomitant Therapy, Permitted Concomitant Therapy
Drug · Procedure · Other
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
18 Years to 66 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 2, 2026, 4:40 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Role of Sweetness in Glucose Regulation

NCT03844230
View directory record Official record
Conditions
Obesity
Interventions
Control - Inhibition, Experimental I- Inhibition, Experimental II- Inhibition, Control- Stimulation, Experimental I- Stimulation, Experimental II- Stimulation, Sensory Evaluation
Other
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
21 Years to 40 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Champaign, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Sep 2, 2026, 4:40 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation

NCT00429416
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
L-leucyl-L-leucine Methyl Ester (LLME), Fludarabine, Cytarabine, Cyclophosphamide, Tacrolimus, Mesna, Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF), Hematopoietic stem cell transplantation (HSCT)
Drug · Biological · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Sep 2, 2026, 4:40 PM EDT
Completed Phase 1 Interventional Results available

A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade

NCT03003676
View directory record Official record
Conditions
Advanced or Unresectable Melanoma Progressing After PD1 Blockade
Interventions
ONCOS-102, Cyclophosphamide, Pembrolizumab
Biological · Drug
Lead sponsor
Targovax Oy
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 7, 2021 · Synced Sep 2, 2026, 4:40 PM EDT
Not listed Not applicable Interventional

Priming With tDCS: Expanding the Window of Recovery in Chronic Stroke

NCT03964467
View directory record Official record
Conditions
Upper Extremity Paresis
Interventions
transcranial direct current stimulation
Device
Lead sponsor
University of the Sciences in Philadelphia
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 5, 2023 · Synced Sep 2, 2026, 4:40 PM EDT
Not listed Phase 2 Interventional

Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma

NCT03400917
View directory record Official record
Conditions
Newly Diagnosed Glioblastoma
Interventions
AV-GBM-1
Biological
Lead sponsor
Aivita Biomedical, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
8
States / cities
La Jolla, California • Newport Beach, California • Orange, California + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Sep 2, 2026, 4:40 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Non-myeloablative Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ Function

NCT06145282
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Briquilimab, Filgrastim, Abatacept, Sirolimus, Cyclophosphamide
Biological · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
4 Years to 100 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 2, 2026, 4:40 PM EDT
Recruiting Not applicable Interventional

Closed-Loop Deep Brain Stimulation for Treatment-Resistant Bipolar Depression

NCT07127913
View directory record Official record
Conditions
Bipolar II Disorder, Bipolar II Disorder, Most Recent Episode Major Depressive
Interventions
Device: Stimulation-ON, Device: Stimulation-OFF, Device: Stimulation -ON Active Control
Device
Lead sponsor
Andrew Krystal
Other
Eligibility
22 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 16, 2025 · Synced Sep 2, 2026, 4:40 PM EDT
Enrolling by invitation Not applicable Interventional

TMS Pilot in Early AD II

NCT06817902
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Intermittent theta burst stimulation active coil, Sham coil
Device
Lead sponsor
HealthPartners Institute
Other
Eligibility
40 Years to 90 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 2, 2026, 4:40 PM EDT
Completed Phase 2 Interventional Results available

Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme

NCT02465268
View directory record Official record
Conditions
Glioblastoma Multiforme, Glioblastoma, Malignant Glioma, Astrocytoma, Grade IV, GBM
Interventions
pp65-shLAMP DC with GM-CSF, unpulsed PBMC and saline, Td, Saline, pp65-flLAMP DC with GM-CSF
Biological · Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
3
States / cities
Gainesville, Florida • Orlando, Florida • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Sep 2, 2026, 4:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pain Sensitivity During Puberty

NCT05145595
View directory record Official record
Conditions
Pain
Interventions
Thermal Sensory Analyzer, Pressure Stimuli, Mechanical Stimuli, Pain Ratings, Thermal pain thresholds, Pressure pain thresholds (PPT), Mechanical temporal summation, Conditioned pain modulation (CPM) efficiency, Offset analgesia efficiency, Cold pain tolerance
Device · Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
9 Years to 16 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Sep 2, 2026, 4:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Perceptual Experience of Argus II Users

NCT05285618
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
Argus II
Device
Lead sponsor
University of California, Santa Barbara
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
3
States / cities
Santa Barbara, California • Baltimore, Maryland • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 31, 2024 · Synced Sep 2, 2026, 4:40 PM EDT
Terminated Not applicable Interventional Results available

Transcranial Direct Current Stimulation (tDCS) and Motor Training for Traumatic Brain Injury (TBI) Survivors

NCT01749735
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Transcranial Direct Current Stimulation, Sham Transcranial Direct Current Stimulation, Armeo training
Device
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Sep 2, 2026, 4:40 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Spatiotemporal Thalamocortical Alterations Underlie Experimental and Chronic Pain

NCT06968689
View directory record Official record
Conditions
Pain
Interventions
transcranial alternating current stimulation (tACS), Sham, transcranial random noise stimulation (tRNS)
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Sep 2, 2026, 4:40 PM EDT